课题基金 / 基金详情

Vascular smooth muscle cell heterogeneity and disease

Vascular smooth muscle cell heterogeneity and disease
血管平滑肌细胞异质性与疾病
批准号:
10559596
负责人:
Michael Simons
金额:
$83.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-03-01 至 2024-12-31

项目摘要

项目成果

Michael Simons的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 血管细胞异质性是一个迷人的,但知之甚少的现象。众多维管细胞 类型在病理条件下经历命运转变。这包括内皮细胞(EC)经历 内皮细胞向间质细胞转化(EndMT),并获得巨噬细胞的某些典型特征 和平滑肌细胞(SMC)。SMC,反过来,也可以获得巨噬细胞样的功能,而骨 骨髓来源的单核细胞可以表达某些EC和SMC标记物,当存在于慢性炎症部位时, 炎症这些细胞的命运转变与各种病理学有关,包括动脉粥样硬化, 动脉瘤、肺动脉高压和海绵状脑畸形。虽然这些细胞的存在 命运转换现在被广泛接受,对SMC经历的起源和特征知之甚少 这些命运的改变。我们的初步数据表明,正常SMC的某些亚群特别 倾向于表型调节并且主要是致病性的。我们假设一小群人 正常SMC的增殖是与SMC池扩张相关的CV疾病发病机制的原因 而靶向这些细胞可能被证明是一种更好、更特异的治疗方法。这是我们的目标 在本申请中,为了定义这些细胞群,确定是什么驱动了它们的致病反应,并开始 确定通过特异性靶向这些SMC来控制CV疾病的治疗方法 子集
英文摘要
Project Summary Vascular cell heterogeneity is a fascinating but poorly understood phenomenon. Numerous vascular cell types undergo fate transitions under pathological conditions. This includes endothelial cells (ECs) undergoing endothelial-to-mesenchymal transition (EndMT) and acquiring certain characteristics typical of macrophages and smooth muscle cells (SMCs). SMCs, in turn, can also acquire macrophage-like features while bone marrow-derived mononuclear cells can express certain EC and SMC markers when present at sites of chronic inflammation. These cells fate transitions have been linked to various pathologies including atherosclerosis, aneurysms, pulmonary hypertension and cavernous cerebral malformations. While the existence of these cell fate transitions is now well accepted, little is known about the origin and characteristics of SMCs undergoing these fate changes. Our preliminary data suggest that certain subpopulations of normal SMCs are particularly prone to phenotypic modulation and are predominately pathogenic. We hypothesize that a small subpopulation of normal SMCs is responsible for pathogenesis of CV diseases associated with expansion of the SMC pool and that targeting these cells might prove to be a better and more specific therapeutic approach. It is our goal in this application to define these cell populations, determine what drives their pathogenic responses and begin identifying therapeutic approaches to controlling CV illnesses driven by specifically targeting these SMC subsets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ischemia/Reperfusion injury and Myocardial edema
  • 批准号:
    10718260
  • 项目类别:
  • 资助金额:
    $61.03万
  • 财政年份:
    2023
  • 负责人:
    Michael Simons
  • 依托单位:
Vascular smooth muscle cell heterogeneity and disease
  • 批准号:
    10356855
  • 项目类别:
  • 资助金额:
    $83.06万
  • 财政年份:
    2021
  • 负责人:
    Michael Simons
  • 依托单位:
Molecular Mechanisms of Arterigenesis
  • 批准号:
    10192382
  • 项目类别:
  • 资助金额:
    $191.79万
  • 财政年份:
    2012
  • 负责人:
    Michael Simons
  • 依托单位:
ERK signaling in arteriogenesis
  • 批准号:
    10433818
  • 项目类别:
  • 资助金额:
    $56.25万
  • 财政年份:
    2012
  • 负责人:
    Michael Simons
  • 依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制